Lung cancer Cancer Malignant neoplasm of bronchus and lung
Conditions
Interventions
The trial is a multicentre randomised phase III trial. Patients are randomised to one of two groups with a 1:1 randomisation:
1. Control group: to receive anti-cancer treatment accord
Sponsors
Velindre NHS Trust (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with histopathologically or cytologically confirmed primary lung cancer of any stage or histology.
Exclusion criteria
Exclusion criteria: 1. Patients with other intrathoracic tumours (e.g. carcinoid, mesothelioma, lymphoma, lung metastases from another primary site) 2. Any previous illness or treatment likely to interfere with protocol treatment or comparisons 3. Known cerebral metastases 4. Haemoptysis of CTC Grade two (symptomatic haemoptysis requiring medical intervention) or above 5. Known bleeding diathesis 6. Known pregnancy or lactation 7. Known allergy to heparin 8. Platelet count lower than 100 x 10^9/l 9. Renal impairment with serum creatinine greater than 150 µmol/l 10. Patients who have received therapeutic anticoagulation in the last 12 months 11. Patients taking Ketorolac
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Venous thrombotic event (VTE) free survival 2. Serious Adverse Events (SAEs) 3. Metastasis-free survival 4. Toxicity 5. Quality of life 6. Levels of breathlessness 7. Anxiety and depression 8. Cost effectiveness and cost utility | — |
Countries
England, United Kingdom
Outcome results
None listed